socalTECH

JANUARY 17, 2017

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has set its estimated IPO pricing range, saying on Tuesday that it expects to price its IPO at between $14.00 and $16.00 The company is selling 4,000,000 shares of its common stock on the NASDAQ Global Select Market as ANAB. READ MORE>>.

Pricing 100

Pricing Avalon Southern California Venice 100

socalTECH

NOVEMBER 14, 2013

San Diego-based medical device manufacturer Tandem Diabetes Care priced its IPO last night, saying it will offer up 8,000,000 shares of its common stock at $15.00 tandem diabetes care diabetic medical device exit merger acquisition tndm' READ MORE>>.

Pricing 153

Pricing San Diego Startup Acquisition 153

socalTECH

MAY 16, 2013

San Diego-based Ambit Biosciences has priced its IPO, saying that it is offering up 8,125,000 shares of its common stock at $8.00 Ambit priced well below its estimated initial public offering range, which had been set at between $13.00 ambit biosciences lifescience merger acquisition' and $15.00 READ MORE>>.

Pricing 138

Pricing San Diego Startup Acquisition 138

socalTECH

APRIL 25, 2013

San Diego-based biopharmaceuticals developer Receptos has set the initial, estimated pricing range for its IPO, saying in a filing Thursday that it now expects its IPO pricing to be between $14.00 receptos merger acquisition lifescience biopharma biopharmaceuticals rcpt exit' and $16.00 READ MORE>>.

Pricing 153

Pricing San Diego Acquisition Funding 153

socalTECH

AUGUST 16, 2021

San Diego-based sales and marketing software developer Seismic has raised $170M in a Series G funding round, the company said this morning, and is now valued at $3 billion. Rowe Price, according to the company. Financial details of that acquisition were not announced. Seismic has now raised $440M in total funding.

San Diego 113

San Diego Coach Sales Training 113

socalTECH

JANUARY 21, 2021

San Diego- and New Jersey-based OncoSec Medical, a publicly traded biotechnology company focused on treatment of cancer, said today that it is raising $42.0M The company said it is offering of 7,711,284 shares of its common stock at a price of $5.45, with an expected close on January 25th.

San Diego 113

San Diego Activity Research Pricing 113

socalTECH

JUNE 27, 2012

San Diego-based ServiceNow , the developer of software-as-a-service for enterprise IT management, is expected to price its IPO Thursday, as the first, technology-focused IPO since the Facebook debacle. The firm, which has set initial pricing range of its IPO at between $15.00 and $17.00 READ MORE>>.

Pricing 145

Pricing San Diego Equity Invest 145

socalTECH

NOVEMBER 15, 2012

San Diego-based ServiceNow said Wednesday evening that it has priced its follow-on public offering at $28.00 The firm is offering up 14,000,000 shares of its common stock, with most of those shares being sold by its existing, venture capital backers. ServiceNow went public on the NYSE as NOW back in June. READ MORE>>.

Pricing 138

Pricing San Diego Venture Capital Capital 138

socalTECH

JUNE 19, 2012

San Diego-based ServiceNow has set the pricing range for its IPO, saying today that it anticipates an initial public offering price for the firm at between $15.00 and $17.00 ServiceNow, which is aiming to trade on the New York Stock Exchange AS NOW, provides software-as-a-service used for enterprise IT management.

Pricing 133

Pricing San Diego Equity Software 133

socalTECH

JULY 25, 2012

San Diego-based Peregrine Semiconductor , the developer of CMOS, RF integrated circuits, has set an estimated pricing range for its its IPO. According to a filing by the firm this morning, it is estimating a IPO price of between $14.00 and $16.00 The firm is offering 5,500,000 shares of its stock in its IPO.

Pricing 145

Pricing San Diego Equity Marketing 145

socalTECH

AUGUST 2, 2010

San Diego-based Trius Therapautics has slashed its IPO offering price, saying today in a filing with the SEC that it will offer 10,000,000 shares of its common stock at $5.00 Tags: trius therapeutics merger acquisition tsrx lifescience exit. and $14.00 READ MORE>>.

Pricing 150

Pricing San Diego Acquisition Marketing 150

socalTECH

AUGUST 8, 2012

San Diego-based Peregrine Semiconductor priced its IPO last night, saying that it will offer up 5,500,000 shares of its common stock at $14.00 Peregrine priced at the low end of its initial estimated pricing range, which was $14.00 The firm will start trading today on the NASDAQ Global Market as PSMI.

Pricing 133

Pricing San Diego Startup Equity 133

socalTECH

JUNE 28, 2012

San Diego-based ServiceNow priced its IPO on Thursday, at $18.00 per share, above its estimated initial offering range of $15.00 The firm is set to trade as NOW on the New York Stock Exchange on Friday. ServiceNow is venture backed by JMI Equity, Sequoia Capital, and Greylock Partners.

Pricing 150

Pricing Marketing San Diego Equity 150

socalTECH

MAY 25, 2011

San Diego-based The Active Network , the operator of sports and community event registration services and websites, priced its IPO Wednesday evening, saying it will sell 11,000,000 shares of its common stock at $15.00 Active priced below its expected initial offering range, which was $16.00 per share.

Activity 124

Activity Pricing Networking San Diego 124

socalTECH

NOVEMBER 4, 2010

San Diego-based Zogenix has updated its S-1, saying this morning the firm intends to offer 6 million shares of its common stock on the Nasdaq Global Market as ZGNX. The firm also said it currently estimates the firm's initial offering price at between $12.00 and $14.00 Zogenix had filed for an IPO in September. READ MORE>>.

Pricing 140

Pricing San Diego Acquisition Marketing 140

socalTECH

JULY 29, 2011

InvenSense , the maker of the motion detecting sensors used in the Wii MotionPlus controller, has set the initial pricing range for its IPO, saying in a filing today that it expects the initial public offering price for its IPO to be between $8.50 and $10.50

Pricing 150

Pricing San Diego Company Companies 150

socalTECH

SEPTEMBER 25, 2013

San Diego-based Evoke Pharma , a biopharmaceuticals firm focused on gastrointestinal disease, raised $25M in an IPO this morning, but is trading down from its IPO debut. evoke pharma merger acquisition biopharmaceuticals lifescience' The company sold 2.1 READ MORE>>.

Pricing 147

Pricing San Diego Acquisition Marketing 147

socalTECH

NOVEMBER 14, 2013

San Diego-based Sorrento Therapeutics announced this morning that it is acquiring fellow, San Diego biotech Concortis Biosystems , to bolster its library of antibodies. The deal is worth approximately $11.6M, based on the recent pricing of Sorrento''s stock. READ MORE>>.

Chief Technology Officer 147

Chief Technology Officer San Diego Acquisition Pricing 147

socalTECH

MAY 20, 2013

San Diego-based security software developer Websense announced this morning that it has signed a definitive agreement to be acquired by private equity firm Vista Equity Partners. Websense said the deal is an approximate premium of 29 percent over the firm''s Friday closing price. The deal is worth approximately $1 billion.

Equity 159

Equity San Diego Software Development Acquisition 159

Xconomy

DECEMBER 10, 2018

ASG Technologies, the Florida-based software company backed by activist hedge fund Elliott Management, has upped its offer for San Diego’s Mitek Systems to $11.50 The stock price of Mitek (NASDAQ:MITK) rose nearly 9 percent on the news, closing at $9.75. per share from $10 apiece. That’s according to a Nov.

Pricing 43

Pricing Acquisition News Software 43

socalTECH

MARCH 15, 2021

San Diego-based Longboard Pharmaceuticals, which is developing medicines for neurological diseases, raised $80M in its IPO last week, selling 5,000,000 shares of its common stock at a price of $16.00 The company is now trading on the Nasdaq Global Market as LBPH.

San Diego 113

San Diego Design Pricing Marketing 113

socalTECH

MAY 9, 2013

San Diego-based biopharmaceuticals developer Receptos is trading flat after its initial public offering, after pricing last night at $14.00 The developer of biopharmaceuticals for treating immune and metabolic diseases priced at the low end of its estimated IPO range, which was $14.00 READ MORE>>.

San Diego 159

San Diego Pricing Venture Capital Acquisition 159

socalTECH

SEPTEMBER 3, 2014

San Diego-based biopharmaceuticals developer Viking Therapeutics has set the estimated pricing for its IPO, saying in a filing Tuesday that it expects to price its IPO at between $10.00 viking therapeutics merger acquisition exit biotech lifescience diabetes vktx' and $12.00 in its offering. READ MORE>>.

San Diego 138

San Diego Pricing Research Acquisition 138

socalTECH

AUGUST 13, 2014

San Diego-based biopharmaceuticals firm Otonomy was up today in early trading, after pricing 6.25 The company priced at the high end of its initial estimated IPO range, which was $14.00 otonomy merger acquisition biotech lifescience otic nasdaq exit' million shares of its common stock at $16.00 READ MORE>>.

Avalon 138

Avalon San Diego Pricing Acquisition 138

socalTECH

OCTOBER 1, 2013

San Diego-bsaed Fate Therapeutics , which is developing biopharmaceuticals base don adult stem cells to treat a number of orphan diseases, is up slightly in trading after its initial public offering this morning. Fate Therapeutics priced at $6.00 in afternoon trading, up around 14.33% over its opening price. and $16.00

San Diego 157

San Diego Pricing Acquisition Marketing 157

Xconomy

JULY 31, 2020

This week the neuroscience drug developer reached a deal to merge with publicly traded Arya Sciences Acquisition Corp II. The biotech IPO market is buzzing but Cerevel Therapeutics is showing that there’s more than one path to the public markets.

Pricing 72

Pricing Acquisition Capital Marketing 72

socalTECH

APRIL 8, 2019

San Diego-based Guardion Health Sciencs , which is developing "condition-specific medical foods and testing technologies" for the ocular health market, has raised $5.0M The company priced its IPO on Friday, selling 1,250,000 shares of its common stock at a price of $4.00 in a small IPO.

San Diego 113

San Diego Pricing Capital Marketing 113

socalTECH

NOVEMBER 8, 2013

San Diego-based biopharmaceuticals firm Santarus has agreed to be acquired by Salix Pharmaceuticals , in a deal worth $2.6 per share in cash for Santarus, which the companies said is a 36 percent premium over Santarus'' closing price on Wednesday. santarus salix pharmaceuticals merger acquisition biopharmaceuticals biotech'

San Diego 164

San Diego Acquisition Pricing Company 164

socalTECH

SEPTEMBER 17, 2018

San Diego-based Senomyx , a developer of artificial flavoring ingredients and sweeteners for the beverage and food market, has been acquired by Switzerland's Firmenich , in a deal worth approximately $72.5M. The deal is an approximately 43 percent premium over the closing price of Senomyx on September 14th. per share in cash.

San Diego 113

San Diego Pricing Marketing Develop 113

socalTECH

MAY 28, 2019

San Diego-based Cibus , a developer of gene editing tools being aimed at use in plant breeding, has pulled its IPO paperwork, saying in a filing that it has decided "not to proceed with the initial public offering of its securities at this time." Cibus had set an estimated initial pricing range of $14.00 READ MORE>>.

San Diego 113

San Diego Pricing Tool Invest 113

Xconomy

AUGUST 11, 2020

The larger company agreed to pay $12 per share for Pfenex (NYSE American: PFNX )—a 57 percent premium to its closing price Monday. San Diego-based Ligand (NASDAQ: LGND ) generates revenue from licensing deals and royalties paid by pharmaceutical companies that use technologies it develops or acquires for their own drug research.

San Diego 98

San Diego Technology Research Pricing 98

socalTECH

DECEMBER 22, 2017

San Diego-based precision medicine developer Ignyta has agreed to be acquired by biopharmaceuticals giant Roche , in a $1.7 The companies said the price is a premium of 74% on Ignyta's closing price on Thursday. The companies said the price is a premium of 74% on Ignyta's closing price on Thursday.

San Diego 113

San Diego Pricing Develop Development 113

socalTECH

SEPTEMBER 23, 2019

A portfolio company of San Diego-based biopharmaceuticals venture investor Versant Ventures is getting set for its IPO this week. Aprea Therapeutics said that estimates its IPO will price between $14.00 and $16.00 per share, which could raise as much as $92.0M for the biotech.

San Diego 113

San Diego Pricing Invest Marketing 113

socalTECH

SEPTEMBER 16, 2019

San Diego-based Qualcomm says it has acquired the remaining interest in RF Holdings Singapore Pte., billion in August of 2019, but that the total purchase price for the rest of RF360 Holdings will be approximately $3.1 the 5G joint venture it has with TDK Corporation. billion.

San Diego 113

San Diego Pricing Technology Product 113

Xconomy

NOVEMBER 5, 2018

San Diego’s ResMed (NYSE: ticker[[RMD]]) announced its intention to buy the privately held tech company on Monday. The purchase price is 25 times MatrixCare’s pro forma 2018 earnings of about $30 million (without taking into account interest, taxes, depreciation or amortization) on anticipated net revenue of about $122 million.

Software 89

Software Acquisition .Net Pricing 89

socalTECH

APRIL 14, 2017

San Diego-based gene therapy developer Tocagen rose in its IPO this morning, after pricing at $10.00 The company priced its IPO at the low end of an initial estimated $10.00 per share last night in its initial public offering. Tocagen was trading up around 24% in morning trading, at $12.45 per share range. READ MORE>>.

San Diego 127

San Diego Pricing Marketing Product 127

socalTECH

JANUARY 20, 2015

San Diego-based biopharmaceuticals developer Tracon Pharmaceuticals said in a regulatory filing today that it is estimated its IPO pricing at between $12.00 tracon pharmaceuticals merger acquisition tcon biotech lifescience exit' and $14.00 READ MORE>>.

San Diego 100

San Diego Acquisition Pricing Invest 100